GeparSepto Trial Demonstrates Improved Survival in High-Risk Early Breast Cancer With Nab-Paclitaxel
December 11th 2017In findings from the phase III GeparSepto trial presented during the 2017 San Antonio Breast Cancer Symposium, long-term disease-free survival rates were improved with neoadjuvant nab-paclitaxel (Abraxane) compared with standard paclitaxel in patients with high-risk early breast cancer.
Read More
Brentuximab Vedotin/AVD Combo Upfront Improves Outcomes in Hodgkin Lymphoma
December 11th 2017The addition of brentuximab vedotin (Adcetris) to doxorubicin, vinblastine, and dacarbazine (A+AVD) reduced the risk of progression and death by 23% in patients with advanced-stage Hodgkin lymphoma (HL) compared with standard ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) chemotherapy, according to results of the phase III ECHELON-1 clinical trial.
Read More
Benefits Maintained With Axi-Cel Long-Term for NHL
December 11th 2017Treatment with the chimeric antigen receptor T-cell therapy axi-cel (axicabtagene ciloleucel; Yescarta) demonstrated improvement in long-term survival rates in patients with refractor, aggressive non-Hodgkin lymphoma, according to updated findings from the pivotal ZUMA-1 trial.
Read More
MAVORIC Study Shows Survival Improved With Mogamulizumab in CTCL
December 10th 2017Mogamulizumab improved progression-free survival in previously treated patients with cutaneous T-cell lymphoma by 4.6 months compared with vorinostat (Zolinza), according to findings from the phase III MAVORIC study.
Read More
Reduced VTE Recurrence in Patients With Cancer From Rivaroxaban Treatment
December 10th 2017Incidence of venous thromboembolism (VTE) recurrence was reduced in patients with cancer with oral rivaroxaban (Xarelto) therapy compared with dalteparin (Fragmin), the current standard of care, according to results from the Select-D pilot trial presented during the 2017 ASH Annual Meeting and Exposition.
Read More
BTK Inhibitor Zanubrutinib Shows Promising Clinical Activity in Non-Hodgkin Lymphoma
December 10th 2017Phase Ib results presented at the 2017 ASH Annual Meeting demonstrated that zanubrutinib (BGB-3111), an investigational BTK inhibitor, had encouraging rates of clinical activity in patients with non-Hodgkin lymphoma, including an overall response rate of 78% among patients with marginal zone lymphoma.
Read More
Exploring Early Ibrutinib Intervention in High-Risk CLL
December 10th 2017Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br />
Watch
Using Checkpoint Blockade Inhibitors in Relapsed Hematologic Malignancies After Stem Cell Transplant
December 10th 2017Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation during the 2017 ASH Annual Meeting.<br /> <br />
Watch
Initial and Maintenance Treatment With Rituximab/Lenalidomide Combo Effective, Safe in MCL
December 10th 2017For patients with mantle cell lymphoma, initial and maintenance treatment with the combination of lenalidomide (Revlimid) and rituximab (Rituxan) were found to be feasible, safe, and elicit clinical activity.
Read More
Survival Improved With Nab-Paclitaxel in TNBC Subset
December 9th 2017Survival rates improved with nab-paclitaxel (Abraxane) therapy compared with paclitaxel in patients with triple-negative breast cancer (TNBC) more than in other patient subsets, according to findings from a post-hoc analysis from the CALGB 40502/NCCTG N063H clinical trial.
Read More
Continued Activity Reported for Pembrolizumab/Eribulin in TNBC
December 9th 2017Updated results of the phase Ib/II ENHANCE1/KEYNOTE-150 study presented at the 2017 San Antonio Breast Cancer Symposium found that the combination of pembrolizumab (Keytruda) and eribulin (Halaven) was associated with a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.
Read More
CTC Detection Associated With High Breast Cancer Recurrence Risk
December 9th 2017Results of a prospective clinical trial demonstrated that the detection of positive circulating tumor cells in the blood 5 years after hormone receptor-positive, HER2-negative breast cancer diagnosis was associated with an increased risk for late recurrence.
Read More
Ovarian Function, Fertility Potentially Protected By Hormone Analog For Women Treated With Chemo
December 8th 2017Treatment with a gonadotropin-releasing hormone analog could potentially preserve fertility and protect ovarian function in premenopausal woman being treated with chemotherapy for early-stage breast cancer, according to the results of a meta-analysis presented at the 2017 San Antonio Breast Cancer Symposium.
Read More
SOLD Trial Maintains Benefit of 1 Year of Adjuvant Trastuzumab for Early Stage HER2+ Breast Cancer
December 8th 2017Results of the phase III SOLD trial maintained the benefit of 12 months of adjuvant treatment with trastuzumab (Herceptin) for patients with early stage HER2-positive breast cancer, as the trial failed to demonstrate noninferiority for 9 weeks of trastuzumab versus the standard 1-year period, when added to chemotherapy.
Read More
DFS Maintained in HR+ Breast Cancer With Fewer Years of AI Therapy
December 8th 2017Disease-free survival is maintained in women with postmenopausal hormone receptor-positive breast cancer treated with aromatase inhibitors, even when the treatment is only given for 2 years in comparison with the standard 5 years of additional aromatase inhibitor therapy, according to findings from the phase III ABCSG-16 trial presented at the 2017 San Antonio Breast Cancer Symposium.
Read More
Enzalutamide Shows Promise in HR+ Breast Cancer
December 7th 2017Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer.
Watch
Getting Genetic Testing to Those Who Need It
December 7th 2017Julie Nangia, MD, assistant professor of Medicine, Baylor College of Medicine, discusses getting genetic testing for patients. While the NCCN has guidelines of who should be tested, it may also be possible for physicians to write a letter of medical necessity for other people, such as Ashkenazi Jewish women, who have higher rates of BRCA mutations.
Watch
Dosing Modifications Shown to Improve Outcomes In Breast Cancer
December 7th 2017Early-stage breast cancer recurrence and mortality was reduced by shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared with standard dosing techniques, according to meta-analysis results presented at the 2017 San Antonio Breast Cancer Symposium.
Read More
The Takeaway Message from the NSABP-47 Trial in HER2-low Breast Cancer
December 7th 2017Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the NSABP B-47 study, which explored the value of trastuzumab (Herceptin) plus standard adjuvant chemotherapy in breast cancer patients with low levels of HER2 protein.
Watch
Disease Control Rate of 45% Achieved With Sacituzumab Govitecan in Heavily Pretreated TNBC
December 7th 2017An overall disease control rate of 45% was achieved with sacituzumab govitecan (IMMU-132) therapy in patients with heavily pretreated metastatic triple-negative breast cancer (mTNBC), according to updated findings of a study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
Read More
Pembrolizumab/Trastuzumab Combo Generates Activity in Trastuzumab-Resistant Breast Cancer Subgroup
December 7th 2017In results from the phase Ib/II PANACEA trial presented at the 2017 San Antonio Breast Cancer Symposium (SABCS), the combination of pembrolizumab (Keytruda) and trastuzumab (Herceptin) achieved an objective response rate (ORR) of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.
Read More
Sir Richard Peto Honored with SABCS's 2017 William L. McGuire Memorial Lecture Award
December 2nd 2017Sir Richard Peto, FRS, a recognized pioneer in epidemiology and health statisticians, will be honored with the William L. McGuire Memorial Lecture Award at the 2017 San Antonio Breast Cancer Symposium (SABCS), to be held December 5 to 9 in San Antonio, Texas. The topic of his award lecture will be announced at a later date, according to a press release from SABCS.
Read More
Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers
November 12th 2017Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />
Watch
Using Antibody-Mediated Neutralization of Soluble MIC to Enhance Response to CTLA-4 Blockade
November 11th 2017Jennifer Wu, PhD, professor, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, discusses how soluble MIC can impact response to anti-CTLA-4 therapy during The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />
Watch
Manipulating Dendritic Cells for Cancer Immunity
November 11th 2017Dendritic cells are an essential target for generating immunity against cancer due to their ability to manipulate the immune system and there are a number of potential methods by which DCs can be utilized for cancer immunotherapy, according to Karolina Palucka, MD, PhD.
Read More
Understanding the Checkpoint Inhibitor-Resistant Disease State
November 11th 2017Metastatic urothelial cancer is a relatively chemotherapy-sensitive malignancy. With contemporary cisplatin-based combination chemotherapy regimens, objective responses are achieved in approximately 50-60% of patients and complete radiographic responses are achieved in approximately 10-20% of patients.
Read More
Treating Patients With Stage IV Lung Adenocarcinoma Without Actionable Oncogenic Drivers
November 11th 2017H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses appropriate treatment for patients with stage IV adenocarcinoma who do not harbor oncogenic drivers.
Watch
Immunotherapies and Combinations in Advanced Urothelial Cancer
November 11th 2017For decades and even to this day, the foundation of metastatic bladder cancer therapy has been cytotoxic chemotherapy. In fact, until recently, the most significant breakthrough in treatment was in the 1980s, when cisplatin-based therapies, specifically MVAC, became the new standard of care.
Read More